Enhanced influenza vaccination for older adults in Europe: a review of the current situation and expert recommendations for the future
Expert Review of Vaccines,
Journal Year:
2025,
Volume and Issue:
unknown
Published: May 1, 2025
Influenza
causes
considerable
morbidity
and
mortality
in
Europe,
particularly
among
older
adults
due
to
comorbidities,
as
well
immunosenescence
inflammaging,
which
contribute
a
diminished
immune
response.
Vaccination
remains
the
most
effective
way
prevent
poor
outcomes;
however,
uptake
is
suboptimal
many
countries
recommend
standard
vaccines
despite
evidence
supporting
better
protection
with
enhanced
(adjuvanted
high-dose)
vaccines.
A
multidisciplinary
group
of
experts
reviewed
burden
influenza
Europe
evaluated
data
on
vaccines,
providing
recommendations
for
their
use
adults.
The
discussed
barriers
vaccination
strategies
increase
uptake.
Improving
against
relies
upon
increasing
vaccine
ensuring
access
that
overcome
age-related
immunological
decline.
Achieving
higher
requires
national
policies
facilitate
equitable
clear
communication
about
eligibility.
Based
available
evidence,
offer
than
hospitalization
complications
National
should
prioritize
over
Limitations
interpretation
include
discrepancies
reporting
influenza-related
medical
encounters,
underreporting
complications,
lack
randomized
studies
comparing
high-dose
adjuvanted
Language: Английский
The effect of influenza vaccination on the rate of dementia amongst older adults
European Journal of Neurology,
Journal Year:
2024,
Volume and Issue:
31(12)
Published: Oct. 6, 2024
Abstract
Background
and
Purpose
Previous
studies
have
reported
conflicting
results
regarding
the
association
between
influenza
vaccination
dementia.
This
was
investigated
in
a
nationwide
register‐based
cohort
study.
Methods
Using
registries,
dementia‐free
adults
aged
≥65
years
Denmark
from
2002
to
2018
without
previous
vaccinations
were
included.
Poisson
regression
facilitated
confounder‐adjusted
comparisons
of
dementia
rates
for
ever
versus
never
vaccinated,
number
within/after
5
first
vaccination.
Sensitivity
analyses
included
stratification
on
age
sex.
Results
Vaccination
during
follow‐up
associated
with
slightly
higher
rate
when
adjusted
sociodemographic
factors
comorbidities,
both
within
after
(incidence
ratio
[IRR]
1.04;
95%
confidence
interval
[CI]
1.03–1.05).
The
decreased
increasing
vaccinations.
highest
amongst
those
only
one
(IRR
1.14;
CI
1.12–1.17)
six
or
more
0.95;
0.93–0.97).
Applying
same
models
control
outcomes
hip
fracture
cancer
resulted
vaccinated
people
6%
7%,
respectively.
Vaccinated
also
had
10%
mortality
rate.
Discussion
Our
do
not
support
case
preventive
effect
risk
general
population,
as
by
some
studies.
However,
found
this
study
is
probably
due
residual
confounding,
indicated
mortality.
Language: Английский